Viktor Grünwald, MD, University Hospital Essen, Essen, Germany, delves into findings from a meta-analysis of various treatment strategies for advanced renal cell carcinoma (aRCC) in the first-line setting. Lenvatinib with pembrolizumab were found to be the efficacious treatment option and had similar overall survival outcomes compared to other combinations. This interview took place at the ASCO GU Cancers Symposium 2024 in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
